Skip to Content
Merck
  • Bromophenacyl bromide, a phospholipase A2 inhibitor attenuates chemically induced gastroduodenal ulcers in rats.

Bromophenacyl bromide, a phospholipase A2 inhibitor attenuates chemically induced gastroduodenal ulcers in rats.

World journal of gastroenterology (2006-09-29)
Mohammad Tariq, Ibrahim Elfaki, Haseeb-Ahmad Khan, Mohammad Arshaduddin, Samia Sobki, Meshal Al Moutaery
ABSTRACT

To study the effect of bromophenacyl bromide (BPB), a phospholipase A2 inhibitor on gastric secretion and to protect chemically induced gastric and duodenal ulcers in rats. Acid secretion studies were undertaken in pylorus-ligated rats with BPB treatment (0, 5, 15 and 45 mg/kg). Gastric and duodenal lesions in the rats were induced by ethanol and cysteamine respectively. The levels of gastric wall mucus, nonprotein sulfhydryls (NP-SH) and myeloperoxidase (MPO) were also measured in the glandular stomach of rats following ethanol induced gastric lesions. BPB produced a dose-dependent inhibition of gastric acid secretion and acidity in rats. Pretreatment with BPB significantly attenuated the formation of ethanol induced gastric lesion. BPB also protected intestinal mucosa against cysteamine-induced duodenal ulcers. The antiulcer activity of BPB was associated with significant inhibition of ethanol-induced depletion of gastric wall mucus, NP-SH and MPO. These findings pointed towards the mediation of sulfhydryls in BPB induced gastrointestinal cytoprotection. BPB possesses significant antiulcer and cytoprotective activity against experimentally induced gastroduodenal lesions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2,4′-Dibromoacetophenone, >98%
Supelco
2,4′-Dibromoacetophenone, for HPLC derivatization, LiChropur, ≥99.0% (HPLC)